rituximab

(redirected from Rituxan)
Also found in: Medical.
Related to Rituxan: Herceptin, Avastin

ri·tux·i·mab

 (rĭ-tŭk′sĭ-măb′)
n.
A chimeric monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and refractory rheumatoid arthritis.

[ri-, origin unknown + tu(mor) + -xi- (alteration of chi(meric), influenced by X, Greek letter chi) + m(onoclonal) a(nti)b(ody).]

rituximab

(rɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat non-Hodgkin's lymphoma
Translations

rituximab

n rituximab m
Mentioned in ?
References in periodicals archive ?
Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered appropriate therapy due to other existing medical conditions (co-morbidities).
Roche Holding AG's arthritis and cancer drug, Rituxan, received approval from the U.
Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).
Roche Holding AG's arthritis and lymphoma medicine Rituxan cut the need for insulin treatment among patients with type 1 diabetes after a year, a study found.
In 1997, Rituxan was the first monoclonal antibody approved for cancer, when it was approved for treating relapsed or refractory low-grade or follicular CD20-positive, B-cell NHL.
ZEVALIN is approved in Europe for the treatment of adult patients with CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL) who are refractory to or have relapsed following RITUXAN (rituximab) therapy.
The potential market size for epratuzumab wasn't there after Rituxan surfaced,'' said Sena Lund, analyst with Cathay Financial in New York.
The First Stage of This Phase III Study Met Its Primary Endpoint and an Additional Futility Analysis Suggested That GA101 Could Show Superiority Compared to Rituxan in First-Line CLL--
Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
The next-generation Rituxan falls under the scope of the original agreement with Genentech, said Biogen spokeswoman Naomi Aoki.
Rituxan was initially approved for the treatment of lymphoma and it was the first mAb to be approved for the treatment of cancer.
Cambridge MA) said that their drug Rituxan failed as a treatment for lupus in a closely-watched study, potentially dashing hopes of a significant sales expansion for the blockbuster biotechnology medicine.